Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.44 |
| ▸ | LPL | P06858 | 4/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28738862 | 0.90 | DGAT1 (0.51) | DGAT1LIPGLPLEGFRMRGPRX4 | |
| SCHEMBL17474563 | 0.88 | DGAT1 (0.54) | DGAT1LIPGLPLEGFRMAPT | |
| SCHEMBL23484499 | 0.87 | LPL (0.48) | DGAT1LIPGLPLEGFRMAPT | |
| SCHEMBL190136 | 0.86 | DGAT1 (0.43) | DGAT1LIPGLPLEGFRNPC1 | |
| SCHEMBL31748489 | 0.85 | DGAT1 (0.52) | DGAT1LIPGLPLEGFRMAPT | |
| SCHEMBL3767677 | 0.85 | DGAT1 (0.52) | DGAT1LIPGLPLEGFRMRGPRX4 | |
| SCHEMBL15884409 | 0.84 | EGFR (0.52) | DGAT1LIPGLPLEGFRHPGD | |
| SCHEMBL15913151 | 0.84 | DGAT1 (0.51) | DGAT1LIPGLPLEGFRMRGPRX4 | |
| SCHEMBL182480 | 0.84 | DGAT1 (0.51) | DGAT1LIPGLPLEGFRMAPK1 | |
| SCHEMBL2415783 | 0.82 | LPL (0.44) | LIPGLPLGAAEGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2439193-B1 | Derivatives of 5,6-bisaryl-2-pyridine-carboxamide, preparation and use thereof in therapeutics as antagonists of urotensin II receptors | SANOFI SA (FR) | 2014-04-23 | — | — | EP | disclosed |
| US-8552201-B2 | 5, 6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS | 2012-05-03 | — | — | US | disclosed |
| EP-2059508-B1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI SA (FR) | 2012-04-11 | — | — | EP | disclosed |
| US-8110579-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI-AVENTIS (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI AVENTIS | 2009-12-24 | — | — | US | disclosed |
| EP-2059508-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-05-20 | — | — | EP | disclosed |
| EP-1841425-A4 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC A DELWARE LTD LIABILIT (BM) | 2009-02-18 | — | — | EP | disclosed |
| US-20080287516-A1 | Phenyl-Substituted Pyrrolidones | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| US-20080287516-A1 | Phenyl-Substituted Pyrrolidones | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| WO-2008020124-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-02-21 | — | — | WO | disclosed |
| EP-1841425-A2 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC A Delware Limited Liability Company (BM) | 2007-10-10 | — | — | EP | disclosed |
| EP-1841424-A2 | SYNTHESIS OF ARYL PYRROLIDONES | IRM, LLC (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081554-A2 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006081562-A2 | SYNTHESIS OF ARYL PYRROLIDONES | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | DGAT1 4221/4885LIPG 2994/4885LPL 3246/4885 |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | DGAT1 4221/4885LIPG 2994/4885LPL 3246/4885 |
| US-20080287516-A1 | Phenyl-Substituted Pyrrolidones | MALT1, FKBP5, PREP | DGAT1 4703/4885LIPG 3627/4885LPL 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.